Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Australian medtech Orthocell hit a new U.S. sales peak for its Remplir™ nerve wrap in October 2026, signaling growing market traction.
Australian medical device maker Orthocell Ltd recorded its strongest single month of U.S. sales for its Remplir™ collagen nerve wrap since the product launched, with 92 units sold in October 2026, according to a company announcement.
Remplir™ is an FDA-cleared device designed to support the repair and protection of peripheral nerves. Developed and manufactured in Australia, the wrap has been positioning itself as a category leader in select international markets as adoption among surgeons continues to build.
Read more Cognizant Deploys 25,000 Workers to Scale OpenAI Enterprise Solutions →
The October milestone represents a notable inflection point for the company's U.S. commercial strategy. Peripheral nerve repair is a specialized surgical segment, and consistent month-over-month volume growth in that space can signal deepening relationships with hospital systems and surgical centers.
Orthocell's progress with Remplir™ comes as the broader medical device industry faces ongoing scrutiny over market penetration timelines and reimbursement pathways for newer surgical tools. Strong unit volume in a single month does not guarantee sustained trajectory, but the record figure offers early evidence that the product is gaining acceptance in a competitive U.S. market.
Continue reading at All Financial Services & Investing.
